Cephalon, U.S. states reach $125 million settlement over generic drugs

Your Health Matters

By Sarah N. Lynch WASHINGTON (Reuters) – Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug Provigil from entering the market, New York Attorney General Eric Schneiderman said on Thursday. The settlement with Cephalon, now owned by Teva Pharmaceuticals, comes a little more than a year after the company struck a $1.2 billion parallel settlement with the Federal Trade Commission.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave